688180 君实生物
2024/06 - 中期
人民币(K¥)
2023/12
人民币(K¥)
2022/12
人民币(K¥)
2021/12
人民币(K¥)
2020/12
人民币(K¥)
经营活动产生之现金流量净额(865,352)(2,004,982)(1,776,201)(605,050)(1,456,377)
投资活动产生之现金流量净额(948,475)(933,191)(437,213)(1,917,802)(740,407)
筹资活动产生之现金流量净额742,384711,8284,613,4782,665,6864,413,523
汇率变动对现金及现金等价物的影响4,7717,55192,266(23,226)(45,768)
现金及现金等价物净增加/(减少)(1,066,673)(2,218,794)2,492,331119,6072,170,972
期初现金及现金等价物余额3,778,1425,996,9363,504,6053,384,9981,214,026
期末现金及现金等价物余额2,711,4693,778,1425,996,9363,504,6053,384,998